Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Coya Therapeutics, Inc. ( (COYA) ) has shared an announcement.
On January 29, 2026, Coya Therapeutics, Inc. entered into a securities purchase agreement with Dr. Reddy’s Laboratories and Greenlight Capital for a private placement of 2,522,727 common shares at $4.40 per share, expected to close on or about January 30, 2026 and raise roughly $11.1 million in gross proceeds. The financing, led by a $10 million investment from Dr. Reddy’s, a subsidiary of Coya’s current strategic collaborator, and $1.1 million from existing shareholder Greenlight Capital, is structured as an unregistered offering under Section 4(a)(2), with Coya committing to register the resale of the shares after closing; the company plans to use the funds to transfer and scale up manufacturing of low-dose IL‑2 to support commercial readiness of COYA 302, while reiterating that the additional capital should accelerate its commercial plans without altering its cash runway guidance into the second half of 2027 and beyond the projected topline readout of its ALSTARS ALS trial.
The most recent analyst rating on (COYA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.
Spark’s Take on COYA Stock
According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.
The score is held down mainly by weak financial quality (ongoing losses and negative cash flow, including very large reported TTM burn) and bearish technical trend (below key moving averages with negative MACD). Offsetting factors include a debt-free balance sheet and positive corporate developments (cash runway extension and clinical/program milestones), but valuation remains difficult given negative earnings and no dividend data.
To see Spark’s full report on COYA stock, click here.
More about Coya Therapeutics, Inc.
Coya Therapeutics, Inc., headquartered in Houston, Texas, is a clinical-stage biotechnology company developing proprietary treatments based on regulatory T cells (Tregs) to address systemic inflammation and neuroinflammation in neurodegenerative, metabolic, and autoimmune diseases. Its pipeline spans Treg‑enhancing biologics, Treg‑derived exosomes, and autologous Treg cell therapies, including COYA 302, an investigational subcutaneous combination of low-dose interleukin‑2 and CTLA‑4 Ig being evaluated in the Phase 2 ALSTARS trial for amyotrophic lateral sclerosis (ALS).
Average Trading Volume: 236,236
Technical Sentiment Signal: Sell
Current Market Cap: $96.25M
See more insights into COYA stock on TipRanks’ Stock Analysis page.